You are here: Industry Insights > Esperion

News List

Esperion Announces Proposed Public Offering FirstWordPharma
December 03, 2021
ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) ("Esperion" or the "Company"), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock ...
Esperion, Daiichi Sankyo Europe Announce Amendment to License, Commercial Agreement americanpharmaceuticalreview
July 01, 2020
Esperion announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe (DSE).
Esperion Announces Commercial Availability of NEXLIZET americanpharmaceuticalreview
June 15, 2020
Esperion announced NEXLIZETTM (bempedoic acid and ezetimibe) tablets, the first approved oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering combination medicine is now available in the U.S.
EC approves Nilemdo™ (bempedoic acid) for lowering cholesterol europeanpharmaceuticalreview
April 10, 2020
The European Commission has granted Esperion approval for Nilemdo, the company has sold commercialisation rights to Daiichi Sankyo.
FDA approves Esperion’s non-statin LDL-C lowering drug pharmaceutical-technology
March 03, 2020
Esperion has announced the US Food and Drug Administration (FDA) has approved Nexlizet (bempedoic acid and ezetimibe).
Esperion’s Bempedoic Acid/ Ezetimibe Tablet Achieves Positive Phase II Results contractpharma
August 30, 2019
Treatment developed to lower elevated LDL-C levels in patients with hypercholesterolemia and type 2 diabetes.
Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review drugs
May 17, 2019
Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review.
Esperion’s phase 3 LDL study raises flags with treatment-arm deaths fiercebiotech
May 03, 2018
Esperion unveiled top-line results from a yearlong phase 3 trial of bempedoic acid, showing it can lower LDL cholesterol levels by an additional 20% over 12 weeks in high-risk patients taking statins.
Esperion's Cholesterol Drug Positive in PhIII Trial biospace
March 08, 2018
Ann Arbor, Michigan-based Esperion Therapeutics Inc. announced that its bempedoic acid for lowering LDL-C cholesterol had positive results in a Phase III clinical trial.
Esperion hits goal in LDL trial, pulls forward NDA target date fiercebiotech
August 10, 2017
The data bolster Esperion's hand as it gets deeper into talks about partnerships